Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRL1068 in Chronic Prosthetic Joint Infection
NCT06621251Phase 2Active, not recruiting
- Sponsor
- Trellis Bioscience
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of calpurbatug in prosthetic joint infection (PJI) (2 arms), sponsored by Trellis Bioscience. Primary endpoint: Efficacy of TRL1068 in eliminating the need for an SoC 2-stage exchange arthroplasty at Day 365. Started Apr 2025; status: active, not recruiting.
02
Drugs
calpurbatug
03
Conditions
prosthetic joint infection (PJI)
Beyond the preview
Go deeper on NCT06621251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06621251.